Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease
China becomes the first country to approve roxadustat for all chronic kidney disease patients with anaemiaAstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia caused by chronic kidney disease (CKD) in non-dialysis-dependent (NDD) patients. This approval, granted by the National Medical Products Administration, is primarily supported by a Phase III trial in NDD-CKD patients with anaemia, in which roxadustat demonstrated a